
The FDA approves Inluriyo-Verzenio combo for ESR1-mutated breast cancer; EMBER-3 data double PFS, with supply chain and diagnostics implications for manufacturers.
Developing and manufacturing highly potent oral solid dose drugs to respond to increasing demand in the industry requires specialized procedures and expertise.






